More on Amgen (AMGN): Q1 beats across the board on strong sales growth and better margins. Combined sales of Neulasta and Neupogen +9%, Xgeva +14%, and Prolia +9%. Operating margins rose to 36.4% from 34.9%.
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs